1. Center for Biologics Evaluation and Research Food and Drug Administration. Guidance for Clinical Trial Sponsors. Establishment and Operation of Clinical Trial Data Monitoring Committees. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) 2006; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatroyInformation/Guidances/ucm124936.pdf (24 February 2017, date last accessed).
2. Committee For Medicinal Products For Human Use (CHMP). Guideline on data monitoring committees 2005; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf (24 February 2017, date last accessed).
3. Group sequential methods for clinical trials with one-sided hypothesis;Demets;Biometrika,1980
4. The futility index. An approach to the cost-effective termination of randomized clinical trials;Ware;Am J Med,1985
5. An investigation of the impact of futility analysis in publicly funded trials;Sully;Trials,2014